Posted by Michael Wonder on 23 Nov 2021
Prilenia receives fast track designation for pridopidine for the treatment of Huntington’s disease
17 November 2021 - Prilenia Therapeutics today announced that the U.S. FDA has granted Fast Track designation to pridopidine for development as a potential treatment for Huntington’s disease.
Pridopidine is a highly selective and potent sigma-1 receptor agonist with an established safety and tolerability profile.
